Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
Posted
February 7, 2024
Views
27,384
Likes
167
Comments
15
Engagement
0.66%
February 7, 2024
27,384
167
15
0.66%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
13:06Now PlayingNovo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic.
For more on this story, please see
--------
Follow Bloomberg for business news & analysis, uptotheminute market data, features, profiles and more
Connect with us on...
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
